PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 557-566

  Bao, Wen ^a   Liu, Ran ^a   Wang, Yonglu ^a,b   Wang, Fei ^a   Xia, Guohua ^a   Zhang, Haijun ^a   Li, Xueming ^b   Yin, Haixiang ^b   Chen, Baoan ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b NANJING TECH UNIVERSITY   (China)

Author keywords

Apoptosis; Daunorubicin; K562 cells; PLGA PLL PEG; Transferrin

Indexed keywords

CASPASE 3; CASPASE 9; DAUNORUBICIN; MACROGOL; NANOPARTICLE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYGLACTIN; POLYGLACTIN POLYLYSINE MACROGOL TRANSFERRIN NANOPARTICLE; POLYLYSINE; PROTEIN BAX; PROTEIN BCL 2; RIBONUCLEASE; TRANSFERRIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; MONOMETHOXY (POLYETHYLENE GLYCOL)-POLY(LACTIDE-CO-GLYCOLIDE)-POLY(LYSINE); POLYESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DAUNORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; MICE; NANOPARTICLES; POLYESTERS; POLYETHYLENE GLYCOLS; POLYLYSINE; TRANSFERRIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921291249     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S75090     Document Type: Article

References (37)

1. Sakhrani NM, Padh H. Organelle targeting: third level of drug targeting. Drug Des Devel Ther. 2013;7:585-599.
2. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8:147-166.
3. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9:615-627.
4. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067-1070.
5. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater. 2009;8:526-533.
6. Zhang J, Sun H, Ma PX. Host-guest interaction mediated polymeric assemblies: multifunctional nanoparticles for drug and gene delivery. ACS Nano. 2010;4:1049-1059.
7. Geels P, Eisenhauer E, Bezjak A, et al. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol. 2000;18:2395-2405.
8. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63:170-183.
9. Umano M, Uechi K, Uriuda T, et al. Tumor accumulation of epsilon-poly-lysines-based polyamines conjugated with boron clusters. Appl Radiat Isot. 2011;69:1765-1767.
10. Tahara K, Furukawa S, Yamamoto H, Kawashima Y. Hybrid-modified poly(d,l-lactide-co-glycolide) nanospheres for a novel cellular drug delivery system. Int J Pharm. 2010;392:311-313.
11. Duncanson WJ, Figa MA, Hallock K, Zalipsky S, Hamilton JA, Wong JY. Targeted binding of PLA microparticles with lipid-PEG-tethered ligands. Biomaterials. 2007;28:4991-4999.
12. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263:1600-1603.
13. Ryschich E, Huszty G, Knaebel HP, Hartel M, Büchler MW, Schmidt J. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer. 2004;40:1418-1422.
14. Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006;5:1909-1917.
15. Tortorella S, Karagiannis TC. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J Membr Biol. 2014;247:291-307.
16. Tortorella S, Karagiannis TC. The significance of transferrin receptors in oncology: the development of functional nano-based drug delivery systems. Curr Drug Deliv. 2014;11:427-443.
17. Petre CE, Dittmer DP. Liposomal daunorubicin as treatment for Kaposi's sarcoma. Int J Nanomedicine. 2007;2:277-288.
18. Guo LT, Chen BA, Liu R, et al. Biocompatibility assessment of polyethylene glycol-poly l-lysine-poly lactic-co-glycolic acid (PEG-PLL-PLGA) nanoparticles in vitro and in vivo. J Nanosci Nanotechnol. 2014;14:1-10.
19. Liu J, Qiu Z, Wang S, Zhou L, Zhang S. A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity. Biomed Mater. 2010;5:065002.
20. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26:57-64.
21. Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine. 2014;9:467-483.
22. Sharma A, Jain N, Sareen R. Nanocarriers for diagnosis and targeting of breast cancer. Biomed Res Int. 2013;2013:960821.
23. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010;363:2434-2443.
24. 2 nanocomposites as a "smart" pH-responsive drug delivery system. Int J Nanomedicine. 2012;7:235-242.
25. Brandsma ME, Jevnikar AM, Ma S. Recombinant human transferrin: beyond iron binding and transport. Biotechnol Adv. 2011;29:230-238.
26. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006;121:144-158.
27. Singh M, Mugler K, Hailoo DW, et al. Differential expression of transferrin receptor (TfR) in a spectrum of normal to malignant breast tissues: implications for in situ and invasive carcinoma. Appl Immunohistochem Mol Morphol. 2011;19:417-423.
28. Szwed M, Matusiak A, Laroche-Clary A, Robert J, Marszalek I, Jozwiak Z. Transferrin as a drug carrier: cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells. Toxicol In Vitro. 2014;28:187-197.
29. Lai H, Nakase I, Lacoste E, Singh NP, Sasaki T. Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. Anticancer Res. 2009;29:3807-3810.
30. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136-151.
31. Fumoto S, Kawakami S. Combination of nanoparticles with physical stimuli toward cancer therapy. Biol Pharm Bull. 2014;37:212-216.
32. Kettiger H, Schipanski A, Wick P, Huwyler J. Engineered nanomaterial uptake and tissue distribution: from cell to organism. Int J Nanomedicine. 2013;8:3255-3269.
33. Packham G, Stevenson FK. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology. 2005;114:441-449.
34. Elkholi R, Floros KV, Chipuk JE. The role of BH3-only proteins in tumor cell development, signaling, and treatment. Genes Cancer. 2011;2:523-537.
35. Agarwal A, Mahfouz RZ, Sharma RK, Sarkar O, Mangrola D, Mathur PP. Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes. Reprod Biol Endocrinol. 2009;7:143.
36. Danial NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res. 2007;13:7254-7263.
37. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677-681.